Background: The most prevalent electrolyte anomaly seen in both hospitalised patients and the general population,
hyponatremia is often defined as serum sodium concentration 135 mEq/L and is linked to higher morbidity and death.
Objective: To study sodium glucose transporter2 (SGLT2) Inhibitors influence in individuals suffering euvolemic and
hypervolemic chronic hyponatremia and it may be a potential new alternative for persistent hyponatremia therapy in
non-diabetic and diabetic patients.
Patients and Methods: That prospective research was carried out on 75 chronic euvolemic or hypervolemic
hyponatremia individuals admitted to internal medicine department in hospitals of Benha university. 2 groups were
formed from participating individuals: 25 hypervolemic hyponatremia or chronic euvolemic individuals in group (1)
who received placebo with additional conventional treatment of chronic hyponatremia (fluid restriction). Group (2)
included 50 hypervolemic hyponatremia or chronic euvolemic individuals who received SGLT2 inhibitor
(empagliflozin). Results: No critical change was seen in serum sodium among day 0 and day 4 or between day 0 and
day 30 in SGLT2 inhibitor untreated patients. Serum sodium was critically lower in day 0 than day 4 (p |
